{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:24:51Z","timestamp":1648794291181},"reference-count":12,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.leukres.2011.02.004","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T12:06:33Z","timestamp":1298721993000},"page":"1153-1155","source":"Crossref","is-referenced-by-count":0,"title":["Nilotinib and dasatinib first-line: Are we ready for imatinib replacement?"],"prefix":"10.1016","volume":"35","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.02.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.004_bib0010","first-page":"122","article-title":"Chronic myeloid leukemia 2010: where are we now and where can we go?","author":"Radich","year":"2010","journal-title":"Hematol Educat Program ASH 2010"},{"key":"10.1016\/j.leukres.2011.02.004_bib0015","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.004_bib0020","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term out come of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.02.004_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08380.x","article-title":"Suboptimal response to imatinib according to 2006\u20132009 European LeukemiaNet criteria: a \u201cgrey zone\u201d at 3, 6 and 12 months identifies chronic myeloid leukemia patients who need early intervention","volume":"152","author":"Breccia","year":"2011","journal-title":"Br H Haematol"},{"key":"10.1016\/j.leukres.2011.02.004_bib0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.02.004_bib0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"issue":"November","key":"10.1016\/j.leukres.2011.02.004_bib0040","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.359.359","article-title":"Excellent outcomes at 3 years with nilotinib 800mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML WP Clinical Trial","volume":"116","author":"Rosti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.004_bib0050","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.02.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.02.004_bib0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up","volume":"116","author":"Shah","year":"2010","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:19:16Z","timestamp":1592349556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261100066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S014521261100066X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.02.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}